Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of polycystic ovary syndrome-A systematic review and meta-analysis.

IF 2.5 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Archives of Physiology and Biochemistry Pub Date : 2024-07-31 DOI:10.1080/13813455.2024.2380422

Xin Tong, Xiaoxuan Song, Yingshi Zhang, Qingchun Zhao

{"title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of polycystic ovary syndrome-A systematic review and meta-analysis.","authors":"Xin Tong, Xiaoxuan Song, Yingshi Zhang, Qingchun Zhao","doi":"10.1080/13813455.2024.2380422","DOIUrl":null,"url":null,"abstract":"Context: Polycystic ovary syndrome (PCOS) is an endocrine gynaecological disorder that affects many women of childbearing age.Objective: To evaluate the efficacy and safety of glucose-like peptide-1 receptor agonists for obese women with PCOS.Methods: We searched the PubMed, Embase, WOS, and Cochrane Libarary databases up to June 2023. Studies were eligible if they were randomised controlled trials (RCTs) comparing GLP-1RAs against any other treatments for patients with PCOS.Results: Overall, a total of 8 RCTs were included in this review, 7 of the RCTs compared GLP-1RAs with metformin, and 1 RCT compared GLP-1Ras with dapagliflozin. Compared with control group, GLP-1RAs were more effective at improving insulin sensitivity, reducing BMI, and resulting in a smaller waist circumference.Conclusions: GLP-1RAs may be a good option for obese women with PCOS, especially those with insulin resistance. However, high-quality studies are also needed in the future to assess the efficacy of GLP-1RAs in women with PCOS.","PeriodicalId":8331,"journal":{"name":"Archives of Physiology and Biochemistry","volume":" ","pages":"1-7"},"PeriodicalIF":2.5000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Physiology and Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13813455.2024.2380422","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Context: Polycystic ovary syndrome (PCOS) is an endocrine gynaecological disorder that affects many women of childbearing age.

Objective: To evaluate the efficacy and safety of glucose-like peptide-1 receptor agonists for obese women with PCOS.

Methods: We searched the PubMed, Embase, WOS, and Cochrane Libarary databases up to June 2023. Studies were eligible if they were randomised controlled trials (RCTs) comparing GLP-1RAs against any other treatments for patients with PCOS.

Results: Overall, a total of 8 RCTs were included in this review, 7 of the RCTs compared GLP-1RAs with metformin, and 1 RCT compared GLP-1Ras with dapagliflozin. Compared with control group, GLP-1RAs were more effective at improving insulin sensitivity, reducing BMI, and resulting in a smaller waist circumference.

Conclusions: GLP-1RAs may be a good option for obese women with PCOS, especially those with insulin resistance. However, high-quality studies are also needed in the future to assess the efficacy of GLP-1RAs in women with PCOS.

查看原文本刊更多论文

胰高血糖素样肽-1 受体激动剂治疗多囊卵巢综合征的疗效和安全性--系统综述和荟萃分析。

背景：多囊卵巢综合征（PCOS）是一种妇科内分泌疾病，影响着许多育龄妇女：评估葡萄糖样肽-1 受体激动剂对患有多囊卵巢综合征的肥胖妇女的疗效和安全性：我们检索了截至 2023 年 6 月的 PubMed、Embase、WOS 和 Cochrane Libarary 数据库。只要是将 GLP-1RA 与其他治疗多囊卵巢综合征患者的方法进行比较的随机对照试验 (RCT) 都符合条件：本综述共纳入了 8 项随机对照研究，其中 7 项研究将 GLP-1RA 与二甲双胍进行了比较，1 项研究将 GLP-1Ras 与达帕利洛嗪进行了比较。与对照组相比，GLP-1RAs在改善胰岛素敏感性、降低体重指数和缩小腰围方面更为有效：结论：对于患有多囊卵巢综合征的肥胖女性，尤其是有胰岛素抵抗的女性来说，GLP-1RAs 可能是一个不错的选择。然而，未来还需要进行高质量的研究，以评估 GLP-1RA 对多囊卵巢综合征女性的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archives of Physiology and Biochemistry ENDOCRINOLOGY & METABOLISM-PHYSIOLOGY

CiteScore

6.90

自引率

3.30%

发文量

期刊介绍： Archives of Physiology and Biochemistry: The Journal of Metabolic Diseases is an international peer-reviewed journal which has been relaunched to meet the increasing demand for integrated publication on molecular, biochemical and cellular aspects of metabolic diseases, as well as clinical and therapeutic strategies for their treatment. It publishes full-length original articles, rapid papers, reviews and mini-reviews on selected topics. It is the overall goal of the journal to disseminate novel approaches to an improved understanding of major metabolic disorders. The scope encompasses all topics related to the molecular and cellular pathophysiology of metabolic diseases like obesity, type 2 diabetes and the metabolic syndrome, and their associated complications. Clinical studies are considered as an integral part of the Journal and should be related to one of the following topics: -Dysregulation of hormone receptors and signal transduction -Contribution of gene variants and gene regulatory processes -Impairment of intermediary metabolism at the cellular level -Secretion and metabolism of peptides and other factors that mediate cellular crosstalk -Therapeutic strategies for managing metabolic diseases Special issues dedicated to topics in the field will be published regularly.